1.02
price down icon2.86%   -0.03
after-market アフターアワーズ: 1.02
loading
前日終値:
$1.05
開ける:
$1.04
24時間の取引高:
135.91K
Relative Volume:
0.62
時価総額:
$61.78M
収益:
-
当期純損益:
$-64.86M
株価収益率:
-0.9107
EPS:
-1.12
ネットキャッシュフロー:
$-55.66M
1週間 パフォーマンス:
+0.00%
1か月 パフォーマンス:
-2.86%
6か月 パフォーマンス:
-55.07%
1年 パフォーマンス:
-65.77%
1日の値動き範囲:
Value
$1.01
$1.05
1週間の範囲:
Value
$0.9901
$1.06
52週間の値動き範囲:
Value
$0.8551
$3.60

Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile

Name
名前
Acumen Pharmaceuticals Inc
Name
セクター
Healthcare (1170)
Name
電話
925-368-8508
Name
住所
427 PARK ST., CHARLOTTESVILLE
Name
職員
52
Name
Twitter
Name
次回の収益日
2025-03-31
Name
最新のSEC提出書
Name
ABOS's Discussions on Twitter

ABOS を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
ABOS
Acumen Pharmaceuticals Inc
1.02 61.78M 0 -64.86M -55.66M -1.12
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-07-26 開始されました Citigroup Buy
2023-12-12 開始されました Deutsche Bank Buy
2023-07-20 再開されました BofA Securities Buy
2023-05-18 開始されました Cantor Fitzgerald Overweight
2022-07-15 開始されました BTIG Research Buy
2022-06-30 開始されました H.C. Wainwright Buy
2022-01-21 アップグレード BofA Securities Neutral → Buy
2021-07-26 開始されました BofA Securities Neutral
2021-07-26 開始されました Credit Suisse Outperform
2021-07-26 開始されました Stifel Buy
2021-07-26 開始されました UBS Buy
すべてを表示

Acumen Pharmaceuticals Inc (ABOS) 最新ニュース

pulisher
May 29, 2025

Halozyme to Participate at Upcoming Investor Conferences - The Malaysian Reserve

May 29, 2025
pulisher
May 19, 2025

FY2025 EPS Estimates for ABOS Reduced by Cantor Fitzgerald - Defense World

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Purchases 41,460 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 18, 2025
pulisher
May 17, 2025

Acumen targets ALTITUDE-AD Phase 2 topline results in late 2026 while advancing subcutaneous Sabirnetug development - MSN

May 17, 2025
pulisher
May 15, 2025

Acumen Pharmaceuticals’ Earnings Call Highlights Progress in Alzheimer’s Treatment - TipRanks

May 15, 2025
pulisher
May 15, 2025

Tower Research Capital LLC TRC Purchases 16,714 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Acumen Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2025 Earnings Call Transcript - Insider Monkey

May 14, 2025
pulisher
May 14, 2025

Barclays PLC Raises Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 14, 2025
pulisher
May 14, 2025

Barclays PLC Raises Stock Holdings in Babcock & Wilcox Enterprises, Inc. (NYSE:BW) - Defense World

May 14, 2025
pulisher
May 14, 2025

Acumen Pharmaceuticals Q1 2025 Financial Update - TipRanks

May 14, 2025
pulisher
May 14, 2025

ABOS Reports Decline in Cash Reserves to Support Operations | AB - GuruFocus

May 14, 2025
pulisher
May 13, 2025

Earnings call transcript: Acumen Pharmaceuticals Q1 2025 financial results and stock gains - Investing.com Nigeria

May 13, 2025
pulisher
May 13, 2025

Acumen (ABOS) Advances in Alzheimer's Treatment Study | ABOS Sto - GuruFocus

May 13, 2025
pulisher
May 13, 2025

ACUMEN PHARMACEUTICALS Earnings Results: $ABOS Reports Quarterly Earnings - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights - The Manila Times

May 13, 2025
pulisher
May 13, 2025

Acumen Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 13, 2025
pulisher
May 11, 2025

Acumen Pharmaceuticals (ABOS) to Release Earnings on Tuesday - Defense World

May 11, 2025
pulisher
May 09, 2025

Acumen Pharmaceuticals Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView

May 09, 2025
pulisher
May 08, 2025

Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference - The Manila Times

May 08, 2025
pulisher
May 06, 2025

Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 - The Manila Times

May 06, 2025
pulisher
May 06, 2025

Upcoming Earnings: Alzheimer's Drug Developer Acumen Pharmaceuticals Reports Q1 Results May 13 - Stock Titan

May 06, 2025
pulisher
May 05, 2025

Halozyme to Participate in the BofA Securities 2025 Healthcare Conference - The Malaysian Reserve

May 05, 2025
pulisher
May 05, 2025

Renaissance Technologies LLC Cuts Stake in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

May 05, 2025
pulisher
Apr 28, 2025

Halozyme to Report First Quarter 2025 Financial and Operating Results - Yahoo Finance

Apr 28, 2025
pulisher
Apr 26, 2025

JPMorgan Chase & Co. Has $1.61 Million Stock Position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Apr 26, 2025
pulisher
Apr 17, 2025

ABOS stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 17, 2025

ABOS stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia

Apr 17, 2025
pulisher
Apr 07, 2025

European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Finansavisen

Apr 07, 2025
pulisher
Apr 03, 2025

Financial Review: Acumen Pharmaceuticals (NASDAQ:ABOS) & Precision BioSciences (NASDAQ:DTIL) - The AM Reporter

Apr 03, 2025
pulisher
Apr 02, 2025

Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation - Stock Titan

Apr 02, 2025
pulisher
Apr 02, 2025

Charles Schwab Investment Management Inc. Acquires 18,004 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors - The Manila Times

Apr 01, 2025
pulisher
Mar 31, 2025

What is HC Wainwright’s Forecast for ABOS FY2029 Earnings? - Defense World

Mar 31, 2025
pulisher
Mar 31, 2025

FY2029 Earnings Forecast for ABOS Issued By HC Wainwright - The AM Reporter

Mar 31, 2025
pulisher
Mar 30, 2025

UBS Group Lowers Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target to $4.00 - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Acumen Pharmaceuticals outlines ALTITUDE AD Phase 2 plans and late 2026 data timeline - MSN

Mar 30, 2025
pulisher
Mar 30, 2025

HC Wainwright Has Lowered Expectations for Acumen Pharmaceuticals (NASDAQ:ABOS) Stock Price - Defense World

Mar 30, 2025
pulisher
Mar 30, 2025

Acumen Pharmaceuticals (NASDAQ:ABOS) Price Target Cut to $11.00 by Analysts at HC Wainwright - The AM Reporter

Mar 30, 2025
pulisher
Mar 29, 2025

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 29, 2025
pulisher
Mar 28, 2025

Acumen Pharmaceuticals’ Earnings Call: Progress Amid Challenges - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Bank of America Securities Sticks to Its Buy Rating for Acumen Pharmaceuticals (ABOS) - The Globe and Mail

Mar 28, 2025
pulisher
Mar 28, 2025

Tesla To $345? Here Are 10 Top Analyst Forecasts For Friday - Benzinga

Mar 28, 2025
pulisher
Mar 28, 2025

UBS Cuts Price Target on Acumen Pharmaceuticals to $4 From $6, Keeps Buy Rating - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Acumen Pharmaceuticals Inc (ABOS) Q4 2024 Earnings Call Highlights: Strong Financial Position ... By GuruFocus - Investing.com Canada

Mar 28, 2025
pulisher
Mar 28, 2025

Acumen Pharmaceuticals Advances Alzheimer’s Treatment Efforts - TipRanks

Mar 28, 2025
pulisher
Mar 27, 2025

Earnings call transcript: Acumen Pharmaceuticals Q4 2024 focuses on Alzheimer’s innovations - Investing.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acumen Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2025
pulisher
Mar 27, 2025

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights - The Manila Times

Mar 27, 2025
pulisher
Mar 27, 2025

Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development - Stock Titan

Mar 27, 2025

Acumen Pharmaceuticals Inc (ABOS) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
大文字化:     |  ボリューム (24 時間):